文献速递妇科

子宫切除术与淋巴结切除术在早期交界性卵巢肿瘤治疗中的作用

Role of hysterectomy and lymphadenectomy in the management of early-stage borderline ovarian tumors.
PubMed 文献 · Gynecol Oncol · 2017-01-26

基于监测、流行病学和最终结果计划的回顾性研究纳入1988至2003年手术治疗的4943例T1期交界性卵巢肿瘤患者,分析子宫切除与淋巴结切除状态与死因特异性生存的关系。多因素分析显示两种手术方式与死因特异性生存无关联,20年生存率各组间无显著差异;年龄≥50岁、T1b-c期及黏液性组织学是生存下降的独立预后因素。

要点

  • T1期交界性卵巢肿瘤中,子宫切除与淋巴结切除与否和20年死因特异性生存率无显著关联。
  • 年龄≥50岁、T1b-c期及黏液性组织学是死因特异性生存下降的独立预后因素。
  • 在T1a期患者中,无论年龄小于50岁或≥50岁,子宫切除与淋巴结切除方式均与死因特异性生存无关联。

核心结论

  • 研究提示,在T1期交界性卵巢肿瘤女性的手术治疗中,子宫切除术和淋巴结切除术均可省略,尤其是对于T1a期病变者,无论年龄如何。

研究设计与样本

  • 这是一项回顾性研究,利用监测、流行病学和最终结果计划识别1988年至2003年间接受手术治疗的T1期交界性卵巢肿瘤患者,共4943例。

主要发现

  • 平均年龄48.7岁,75.3%为T1a期,中位随访15.6年,159例(3.2%)死于交界性卵巢肿瘤。
  • 1909例(38.6%)行子宫切除术,1295例(26.2%)行淋巴结切除术;最常见为两者均未行(46.5%),其次为仅子宫切除(27.3%)、仅淋巴结切除(14.9%)和两者均行(11.3%)。
  • 子宫切除和淋巴结切除的手术模式在年龄、种族、婚姻状况、登记地区、诊断年份、组织学类型、亚期和肿瘤大小间显著不同(所有P<0.001)。
  • 多因素分析显示,子宫切除和淋巴结切除的手术模式与死因特异性生存无关联:两者均未行20年生存率96.7%,仅子宫切除94.5%,仅淋巴结切除95.7%,两者均行95.2%(校正P>0.05)。
  • 年龄≥50岁、T1b-c期和黏液性组织学仍是死因特异性生存下降的独立预后因素(所有P<0.05)。

临床怎么用

  • 作者认为,对于T1期交界性卵巢肿瘤女性,尤其是T1a期病变者无论年龄,手术治疗中可省略子宫切除术和淋巴结切除术。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine survival of women with stage T1 borderline ovarian tumors (BOTs) stratified by hysterectomy and lymphadenectomy status at surgery. METHODS: This is a retrospective study examining The Surveillance, Epidemiology, and End Results Program to identify surgically-treated stage T1 BOTs between 1988 and 2003 (n=4943). Association of surgery patterns and cause-specific survival (CSS) was examined in multivariable analysis. RESULTS: Mean age was 48.7. The majority had stage T1a disease (75.3%). Median follow-up was 15.6years and 159 (3.2%) women died of BOTs. Hysterectomy and lymphadenectomy were performed in 1909 (38.6%) and 1295 (26.2%) cases, respectively. Most commonly, neither procedure was performed (46.5%), followed by hysterectomy alone (27.3%), lymphadenectomy alone (14.9%), and both procedures (11.3%). Surgery patterns for hysterectomy and lymphadenectomy significantly differed across age, ethnicity, marital status, registry area, year at diagnosis, histology type, sub-stage, and tumor size (all, P<0.001). On multivariable analysis, surgery patterns for hysterectomy and lymphadenectomy were not associated with CSS: 20-year rates for neither hysterectomy and lymphadenectomy 96.7%, hysterectomy alone 94.5%, lymphadenectomy alone 95.7%, and both procedures 95.2% (adjusted-P>0.05). Age≥50, T1b-c stages, and mucinous histology remained independent prognostic factors for decreased CSS (all, P<0.05). Among 3723 women with stage T1a disease, hysterectomy and lymphadenectomy patterns were not associated with CSS in 2115 women aged <50 (P=0.14) and 1608 women aged ≥50 (P=0.48). CONCLUSION: Our study suggests that both hysterectomy and lymphadenectomy may be omitted in the surgical management of women with stage T1 BOTs, especially for those with T1a disease regardless of age.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Matsuo K, Machida H, Takiuchi T, et al. Role of hysterectomy and lymphadenectomy in the management of early-stage borderline ovarian tumors. Gynecol Oncol. 2017. PMID: 28131526. doi:10.1016/j.ygyno.2017.01.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。